Frankfurt - Delayed Quote EUR

IntelGenx Technologies Corp. (0IL.F)

0.1070

-0.0100

(-8.55%)

At close: 8:16 AM GMT+2

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial. MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progr

GlobeNewswire 18 days ago

IGXT
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted abbreviated new drug application (“ANDA”) for Buprenorphine Buccal Film. The CRL includes a request for additional Pharmaceutical Q

GlobeNewswire 21 days ago

IGXT
IntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call Transcript

IntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call Transcript March 21, 2024 IntelGenx Technologies Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to the IntelGenx Fourth Quarter and Full Year 2023 Results Conference Call. [Operator Instructions] Please […]

Insider Monkey last month

IGXT
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. "We successfully executed against key strategic priori

GlobeNewswire last month

IGXT
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow

SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024. An accompanying conference call will be hosted by Dwight Gorham, Chief Executive Officer and Andre Godin, President and Chief Financial Officer to discuss the results and provide a business update. De

GlobeNewswire last month

IGXT
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx Corp.”), has entered into a third amended and restated loan agreement dated as of March 8, 2024 (amending the second amended and restated loan agreement dated as of September 30, 2023) (the “Loan Agreement”) with atai Life Sciences AG (“atai”), pursuant to which, among other things, atai has agreed to

GlobeNewswire last month

IGXT
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering

SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A Preferred Stock”), par value $0.00001 per share, at an offering price of $10.00 per share (the “Offering”), for a maximum Offering amount of $20,000,000. Holders of the Series A Preferred Stock will be entitled to receive cumulativ

GlobeNewswire 2 months ago

IGXT
IntelGenx Launches Preferred Share Regulation A Offering

SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A Preferred Stock”), par value $0.00001 per share, at an offering price of $10.00 per share (the “Offering”), for a maximum Offering amount of $20,000,000. Holders of the Series A Preferred Stock will be entitled to receive cumulativ

GlobeNewswire 2 months ago

IGXT
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform

SAINT LAURENT, Quebec, Feb. 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced positive results from a proof-of-concept (“POC”) study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm® platform in healthy dogs and cats. The POC study was conducted through a research collaboration with the University Prince Edward Island (“UPEI”), one of North America’s leading vete

GlobeNewswire 2 months ago

IGXT
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®

SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license agreements (collectively the “Agreements”) with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC (“Covenant Animal Health”). Under the terms of the development agreement, Covenant Animal Health will fund development and manufacturing of a VetaFilm®-based drug (the “Product”). The license ag

GlobeNewswire 4 months ago

IGXT
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000

SAINT LAURENT, Quebec, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the previously announced subsequent non-brokered private placement (the “Subsequent atai Subscription”) of 750 units (“US Units”) with atai Life Sciences AG (“atai”) for aggregate gross proceeds of US$750,000, on the same terms as the August 31, 2023, offering of units (the “Initial Offering” and together with the Subsequent atai Sub

GlobeNewswire 4 months ago

IGXT
IntelGenx Announces Changes to its Board of Directors

SAINT LAURENT, Quebec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors of the Company (the “Board”) effective December 2, 2023. Mr. Stegert and Dr. Rao were the Board designees for atai Life Sciences AG (“atai”) pursuant to the purchaser rights agreement by and between the Company and atai (the “Rights Agreement”). On December 2, 2023, the

GlobeNewswire 4 months ago

IGXT
IntelGenx Announces Shareholder Approval of Financing Transactions

SAINT LAURENT, Quebec, Nov. 28, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) is pleased to announce that, at its meeting held earlier today (the “Special Meeting”), the shareholders (the “Shareholders”) voted to approve all proposals related to financing transactions involving atai Life Sciences AG (“atai”) previously disclosed by the Company on August 31, 2023 (the “Financing Transactions”). In order for the Company to proceed with

GlobeNewswire 4 months ago

IGXT
IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease

Phase 2 MONTPARK trial expected to begin recruiting patients in Q1 2024SAINT LAURENT, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that the Swedish Medical Products Agency (“MPA”), the Swedish Ethical Review Authority, and the Regional Biobank Centre have approved the planned clinical study to investigate the use of IntelGenx’s Montelukast VersaFilm® for the treatment of Parkinson’s Disease (“PD”). PD is the secon

GlobeNewswire 5 months ago

IGXT
IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting

SAINT LAURENT, Quebec, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) wishes to remind its shareholders of record as of October 2, 2023 (the “Shareholders”) of the importance of a vote FOR the various proposals detailed below at the upcoming special meeting of Shareholders to be held on November 28, 2023 (the “Special Meeting”) as a virtual meeting only. At the Special Meeting, Shareholders will be asked to vote: to amend the

GlobeNewswire 5 months ago

IGXT
IntelGenx Technologies Corp. (PNK:IGXT) Q3 2023 Earnings Call Transcript

IntelGenx Technologies Corp. (PNK:IGXT) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Greetings. Welcome to IntelGenx’s Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this call is being recorded. I will now turn […]

Insider Monkey 5 months ago

IGXT
IntelGenx Reports Third Quarter 2023 Financial Results

SAINT LAURENT, Quebec, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. 2023 Third Quarter Financial Summary: Revenue was $318,000, compared to

GlobeNewswire 5 months ago

IGXT
IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray

IntelGenx to Manufacture and Supply Three New Filmstrip Products: CBD20, THC10, and THC10:CBD10SAINT LAURENT, Quebec, Nov. 06, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it and Tilray Brands Inc. (“Tilray”) have entered into a further amendment (the “Second Amendment”) to their November 2018 license, development and supply agreement for the co-development and commercialization of cannabinoid-infused VersaFilm® products, sett

GlobeNewswire 5 months ago

IGXT
IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow

SAINT LAURENT, Quebec, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its third quarter 2023 financial results after market close on Thursday, November 9, 2023. An accompanying conference call will be hosted by Dwight Gorham, Chief Executive Officer, Andre Godin, President and Chief Financial Officer, and Dr. Horst G. Zerbe, Chairman, to discuss the results and provide a b

GlobeNewswire 5 months ago

IGXT
IntelGenx Provides RIZAFILM® U.S. Commercialization Update

Receives first purchase order from Gensco® PharmaSAINT LAURENT, Quebec, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has received the first purchase order (“PO”) for RIZAFILM®1 from its commercial partner in the United States, Gensco Pharma (“Gensco®”). The PO triggers an upfront order deposit payment. A pre-specified milestone payment to IntelGenx from Gensco® is also payable upon transfer of NDA. Both payments w

GlobeNewswire 7 months ago

IGXT

Performance Overview

Return	0IL.F	S&P 500
YTD	+10.31%	+6.92%
1-Year	-23.02%	+25.26%
3-Year	-75.23%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

IntelGenx Technologies Corp. (0IL.F)

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call Transcript

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow

IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering

IntelGenx Launches Preferred Share Regulation A Offering

Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform

IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®

IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000

IntelGenx Announces Changes to its Board of Directors

IntelGenx Announces Shareholder Approval of Financing Transactions

IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease

IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting

IntelGenx Technologies Corp. (PNK:IGXT) Q3 2023 Earnings Call Transcript

IntelGenx Reports Third Quarter 2023 Financial Results

IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray

IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow

IntelGenx Provides RIZAFILM® U.S. Commercialization Update

Performance Overview